TAGBIKO
Live / Allowed — Notice of allowance issued (as of 15 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 29 May 2026 filing date already counts against anyone who files later.
Record
- Serial number
- 99852895
- Mark type
- Stylized text
- Filed
- 29 May 2026
- Published for opposition
- 21 Jul 2026
- Attorney of record
- Kristen Ruisi
Goods and services
- Class 005 — Pharmaceuticals: Medicines for human purposes for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs for medical use being medicines for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical use, namely, for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical use, namely, for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; injectable pharmaceuticals for treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude medicines for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biochemical preparations for medical use, namely, the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
Owner
- BeOne Medicines I GmbH, Basel, CH
- BeOne Medicines I GmbH, Basel, CH
Prosecution history
- 15 Sept 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 21 Jul 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 Jul 2026 — PUBLISHED FOR OPPOSITION
- 15 Jul 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Jun 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Jun 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 Jun 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 Jun 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 22 Jun 2026 — NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
- 22 Jun 2026 — EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
- 22 Jun 2026 — COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
- 22 Jun 2026 — EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
- 17 Jun 2026 — ASSIGNED TO EXAMINER
- 29 May 2026 — APPLICATION FILING RECEIPT MAILED
- 29 May 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED